BioTuesdays

Category - Markets

rhythm pharmaceuticals
Markets

Stifel ups Rhythm Pharma to buy; PT held at $34

Stifel upgraded Rhythm Pharmaceuticals (NASDAQ:RYTM) to “buy” from “hold” but maintained its price target at $34, saying the stock is at an attractive entry point ahead of near-term Phase 3 results. The stock closed at...

July 12, 2019
maxim Group Logo
Markets

Maxim cuts PTs on five biotech stocks

Maxim Group reduced price targets for five biotech stocks, citing data troughs, financing conditions and political factors, which may be further compounded by a lack of catalysts and increasing operating expenses...

July 9, 2019
Fortress Biotech
Markets

Roth starts Fortress Biotech at buy; PT $4

Roth Capital Partners launched coverage of Fortress Biotech (NASDAQ:FBIO), which acquires and develops biopharmaceutical assets, with a “buy” rating and price target of $4. The stock closed at $1.55 on July 1.

July 1, 2019
Merus Logo
Markets

Roth starts Merus at buy; PT $20

Roth Capital Partners launched coverage of Netherlands-based Merus NV (NASDAQ:MRUS) with a “buy” rating and $20 price target. The stock closed at $14.12 on June 27.

June 28, 2019